7 Strategies to Build Payer Evidence for a Wound Care Product

Payers, MACs, and IDN value analysis committees increasingly discount trial-only claims for CTPs/CAMPs, NPWT, and advanced dressings. A single RCT with a closure endpoint, run in a narrow population, rarely answers the questions a policy reviewer or auditor actually asks. A payer evidence file for a wound care product has to be designed backward from the criteria that decide coverage, then maintained after launch.

The seven strategies below run from foundational evidence design to ongoing surveillance. Each one is scoped by what it can and cannot prove, because reviewers in this space read limitations as closely as results.

1. Map payer evidence requirements first

Evidence programs usually start with what the company wants to claim. Payer evidence starts with what the policy asks. A requirements matrix built from local coverage determinations (LCDs) and their billing articles (LCAs), commercial medical policies, and value analysis committee (VAC) criteria turns coverage language into a testable checklist, and it exposes gaps before you spend money on a study that cannot fill them.

Consider an illustration. A DFU CTP team tabulates the criteria in the policies it cares about and finds that several require documented duration of prior standard-of-care treatment before the product is used. Its pivotal trial enrolled patients after a run-in period, but never recorded what care they received or for how long. The trial is sound, yet it cannot support that criterion. The gap is visible only because someone read the policy line by line.

Medicare skin substitute policy has shifted repeatedly, so treat the matrix as a living document and anchor every row to the current CMS or MAC page and its effective date. On December 24, 2025, the A/B MACs withdrew the DFU and VLU skin substitute LCDs days before they were to take effect, leaving Novitas, First Coast, and CGS with their existing policies and other jurisdictions deciding coverage case by case. Separately, CMS began paying most skin substitutes as incident-to supplies at a flat rate of about $127 per square centimeter on January 1, 2026, and the CY 2027 Physician Fee Schedule proposed rule would extend national pricing to non-sheet products.

1. Collect current LCDs, LCAs, and commercial payer policies for your product category and wound types.
2. Tabulate each criterion: population, wound characteristics, prior treatment, product use limits, documentation, and outcome expectations.
3. Mark each criterion as covered, partial, or missing against your existing evidence.
4. Assign an owner and a target date to every partial or missing row.

The common mistake is designing studies around the claim you want to make rather than the criteria the policy states. A strong result on an endpoint no policy references buys little.

Measure the percentage of policy criteria supported by existing evidence, and the number of gaps closed per quarter. Both are crude, but they force prioritization and give leadership a defensible status view.

2. Define payer-relevant endpoints in advance

Endpoints are where payer disputes start. If the protocol leaves the definition of closure, the index wound, or the assessment window open, a reviewer can argue that results were shaped after the fact. Pre-specification removes that argument, and matching the language of target policies removes another: that the study measured something different from what the policy cares about.

Typical payer-facing endpoints include complete closure within a fixed window, time to closure, and percent area reduction at 4 weeks. Percent area reduction is used as an early predictor of healing in DFU and VLU literature, but it is a surrogate, and not every policy accepts it as a substitute for closure. Confirm policy by policy rather than assuming.

As an illustration, imagine a protocol and statistical analysis plan (SAP) that fix the closure definition (full epithelialization with no drainage or dressing requirement, confirmed at a second visit two weeks later, consistent with FDA guidance), the index wound rule for patients with multiple ulcers, and the assessment window before the first patient is enrolled. Any later analysis is then traceable to a written decision.

1. Review endpoint language in each target policy and note the exact wording and time frames.
2. Write definitions into the protocol and SAP, including who assesses closure and how it is confirmed.
3. Document censoring rules, handling of missing visits, and treatment of patients lost to follow-up or amputated.
4. Version-control the SAP and record the date it was locked.

The common mistake is relying on ad hoc or surrogate endpoints that do not match policy language, often because they are easier to hit in a small sample. Measure an alignment score: the share of primary and key secondary endpoints whose definition and window match the language in your target policies.

3. Use real-world data to complement RCTs

RCTs establish efficacy under controlled conditions. Payers, however, cover the product as used in SNFs, home visits, and hospital-based wound centers, where patients are older, more comorbid, and less adherent than trial participants; most real-world wound center patients would have been excluded from major wound care RCTs. Real-world wound care data (RWD) addresses that external validity question.

Take an illustration: a manufacturer builds real-world DFU and VLU cohorts and shows how routine-care patients differ from its trial population in wound size, duration, and comorbidity burden, and how closure rates and time to closure look in that population. The value is less the headline rate than the description of who actually gets treated and how.

Setting coverage matters. A dataset that captures only one care setting will misrepresent utilization and outcomes elsewhere, so check what your source covers before designing anything.

1. Select a dataset with wound type and care-setting coverage that matches your target policies.
2. Define the cohort, index date, exposure, and outcomes in a written protocol.
3. Run sensitivity checks on inclusion rules, outcome definitions, and missing data handling.
4. Document data provenance, extraction dates, and missingness for each key variable.

The common mistake is presenting RWD results without stating confounding and documentation limitations. Charting quality varies, wound measurements may be inconsistently recorded, and treatment selection is not random. Data captured as structured fields in a purpose-built wound care EHR narrows the documentation problem, and particularly selecting a wound care-specific electronic data capture software with AI-powered measurement capabilities improves clinical trial speed and reduces common errors.

Measure cohort size, data completeness for key covariates such as wound area, duration, and diabetes status, and representativeness across care settings.

4. Run comparative effectiveness studies

A payer deciding on coverage is implicitly asking “compared to what?” Single-arm results, whether from a trial or a registry, do not answer it. Comparative effectiveness studies place the product against what patients would actually receive otherwise, using matching or weighting to reduce confounding when randomization is not available.

As a hypothetical illustration, consider a propensity-weighted comparison of a CTP versus standard care in DFUs. Covariates include baseline wound area, wound duration, HbA1c, infection status, and care setting. After weighting, the team checks balance, estimates the difference in closure at 12 weeks with a confidence interval, and reports an E-value to show how strong an unmeasured confounder would need to be to explain the result away. The E-value does not eliminate bias. It quantifies how fragile the estimate is.

1. Pre-specify the comparator, covariate set, and weighting or matching method before looking at outcomes.
2. Check covariate balance after adjustment and report it.
3. Estimate effects with confidence intervals, not p-values alone.
4. Report sensitivity analyses, including E-values and alternative model specifications.

The common mistake is choosing a convenient comparator, such as an untreated historical group, or omitting covariates like wound size and duration that strongly predict healing. Either can produce an impressive and worthless effect.

Measure standardized mean differences for each covariate (a common working threshold is below 0.1), the effect estimate with its confidence interval, and the E-value. Comparative effectiveness studies also depend on the data supporting the design, so revisit strategy 3 before committing.

5. Structure PMCF as reusable payer evidence

Under EU MDR, manufacturers must run post-market clinical follow-up (PMCF) as part of continuing clinical evaluation for applicable devices. Many teams treat it as a compliance file, written for a notified body and then shelved. That wastes a longitudinal dataset on safety and performance that payers also want to see. Confirm current MDR requirements and your notified body’s expectations directly, since they vary by device class and evolve through guidance.

The design choices that make PMCF reusable are made early: endpoints, sample size rationale, follow-up schedule, and reporting cadence. If they are set only to satisfy a regulator, the output may not map to payer criteria at all.

As an illustration, imagine a PMCF report on a dressing that is repackaged into a short payer-facing summary showing adverse events and healing performance over time, with population and methods described the same way the payer’s policy describes them.

1. Write the PMCF plan with endpoints reviewed against your requirements matrix from strategy 1.
2. Justify sample size and follow-up duration explicitly, including what the study can and cannot detect.
3. Schedule interim analyses so evidence arrives before payer review cycles, not after.
4. Build a payer-facing summary template alongside the regulatory report.

The common mistake is treating PMCF as a file that is never repurposed. A related one is promising payer-grade conclusions from a study sized only for safety surveillance.

Measure PMCF enrollment and follow-up completion rates, and time from data lock to payer-ready summary. A long lag usually means the reporting structure was never designed for dual use.

6. Identify true usage patterns and real competitors

Evidence plans often assume where a product is used and what it competes with. Utilization data can contradict both. Volume may concentrate in a care setting your studies never covered, or the alternative that a payer reviewer would name may be a different product class, or standard care, rather than the rival your commercial team tracks.

Imagine a team that discovers, from utilization data, that most of its volume comes from a care setting where its evidence contains almost no patients. Its trials were run in hospital-based wound centers; the reviewer’s question is about the setting where the product is really used. That is a defensive problem for coverage and an offensive one for positioning.

1. Pull utilization by care setting and wound type from a source such as Intellicure Analytics’ Wound Care Industry Dashboard.
2. Map that distribution against your evidence coverage from the matrix in strategy 1.
3. Identify which products and approaches are actually substituted in each setting.
4. Reprioritize studies toward high-volume, low-evidence combinations.

The common mistake is assuming the named competitor is the payer’s comparator without checking. Payers often benchmark against lower-cost standard options, and a comparative study built on the wrong comparator answers a question nobody asked.

Measure the share of utilization covered by evidence, and the change in evidence coverage of your top care settings over time. Note that utilization data reflects billed or recorded use, so treat it as a strong indicator rather than a full census.

7. Package and publish evidence for payer use

Evidence that sits in internal reports carries little weight. Peer-reviewed publication provides external scrutiny that reviewers can cite, and a payer dossier organizes the material so a medical director can find what the policy criteria require without reconstructing it.

As an illustration, consider a one-page evidence summary and a methods appendix submitted with a coverage reconsideration request. The summary maps each policy criterion to a study and result. The appendix gives populations, endpoint definitions, analysis methods, and limitations, so a reviewer can judge quality without contacting the manufacturer.

1. Plan manuscripts and realistic timelines, since peer review can take many months.
2. Build the dossier around the requirements matrix, one row per criterion, with citations.
3. Verify current reconsideration and public comment procedures with the specific MAC or payer before submitting, as processes and deadlines change.
4. Track citations of your work in policies, guidelines, and later studies.

The common mistake is leading with marketing language instead of methods and stated limitations. Adjectives lower credibility with this audience. A dossier that states what the evidence does not show reads as more trustworthy than one that claims everything.

Measure publications accepted, payer dossier requests fulfilled, and policy citations of your evidence. The last is slow to move and the most meaningful.

Sequencing the work: where should you spend the first dollar?

Start with the requirements matrix and endpoint definitions (strategies 1 and 2). They cost little, they determine whether everything after is usable, and they often show that a planned study would have missed the criteria that matter. Then let the gaps decide the middle of the program: real-world data when the gap is population or care-setting representativeness, a comparative effectiveness study when the gap is “compared to what?”, and PMCF design when a regulatory obligation already exists and can be made to do double duty. Usage analysis (strategy 6) should inform all three choices. Packaging and publication come last, because they can only present what the earlier work produced.

If you are assessing which gaps to close first, or need real-world data, comparative studies, or PMCF support scoped to payer criteria, learn more about our services.